We have previously identi®ed NPDC-1, a neural factor involved in the control of proliferation and dierentiation, and we have shown that the stable introduction of NPDC-1 into transformed cells down-regulates cell proliferation both by increasing the generation time and by suppressing transformed properties. The data presented here indicate that, in vitro, NPDC-1 is able to interact with the transcription factor E2F-1 and some cell cycle proteins, such as D-cyclins and cdk2. In addition, two-hybrid experiments in mammalian cells show that the interaction between NPDC-1 and E2F-1 can also occur in vivo. This interaction reduces the binding of E2F-1 to DNA and its transcriptional activity. Taken together, the data suggest that NPDC-1 could in¯uence cell cycle progression and neural dierentiation through its association with E2F-1. Oncogene (2000) 19, 5000 ± 5009.
Introduction
In most cell lineages, terminal dierentiation requires permanent withdrawal from cell cycle. The progression of the cycle is largely dependent on the interactions between cyclins, cyclin-dependent kinases and cdks inhibitory proteins. These latter are grouped into two subfamilies: the proteins of the p15/p16/p18/p19 subfamily regulate essentially cyclinD/cdk4,6 activities whereas the p21/p27/p57 subfamily have a broader speci®city and regulate most of the cyclin/cdk activities (reviewed by Sherr and Roberts, 1999) . The cell cycle is also dependent on the activity of transcription factors of the E2F family, designated E2F-1 to E2F-6, which bind to DNA under the form of heterodimers with DP-1 and DP-2 (Helin et al., 1993a; Tao et al., 1997) . It has been shown that E2F-1 activates the expression of genes involved in the G1/S transition and in the onset of the S phase (Johnson et al., 1993; MuÈ ller et al., 1997) . The activity of E2F is strongly regulated by its association to pocket proteins pRB, p107 and p130 (Hurford et al., 1997) . More especially, the association of E2F-1 to pRB acts both to limit the amount of pRB-free active E2F-1 and to convert DNA-bound E2F-1 into a transcriptional repressor (Helin et al., 1993b; Weintraub et al., 1995; Zacksenhaus et al., 1996; Ross et al., 1999) . The phosphorylation of the proteins of pRB family by cyclin D/cdk4,6 and cyclinE/cdk2 leads to the dissociation of their complexes with E2F-1 (Knudsen and Wang 1997) . Consequently, in late G1, E2F-1 becomes able to activate the expression of genes transcribed from promoters including E2F-1-binding sites. Afterwards, when the cells have entered S phase, cyclin A/cdk2 can bind and phosphorylate E2F-1, leading to the inhibition of its DNA-binding activity (Xu et al., 1994; Kitagawa et al., 1995; Krek et al., 1995) . This regulation of E2F-1 activity likely contributes to the decision of the cells either to enter S phase or to undergo dierentiation (reviewed by Helin, 1998) .
Several regulators of the cell cycle have been shown to be involved in cell dierentiation and survival. The analysis of RB-de®cient mice has suggested that RB is likely involved in neural dierentiation during embryonic development (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) . More recently, it has been shown that pRB can cooperate with MyoD-1 to transactivate the expression of genes implicated in myogenic dierentiation (Novitch et al., 1999) . In addition, when myoblasts enter their dierentiation, MyoD1 stimulates also the expression of p21 that inhibits cyclin D1-dependent kinase activity. Consequently, MyoD1 stays under a hypophosphorylated and active form, able to stimulate the expression of other transcriptional factors and then of muscle-speci®c genes (Guo et al., 1995; Halevy et al., 1995; Skapek et al., 1995) . In parallel, the inhibition of pRB phosphorylation by p21 allows pRB to keep its active form that interacts with E2F-1 and thus to lock myogenic cells in a quiescent and dierentiated state (Schneider et al., 1994) . However, the correlations between the control of cell cycle, the regulation of dierentiation and the maintenance of the dierentiated state remain largely mysterious for most cell lineages, and more especially for neural cells and their precursors.
Looking for genes that might be involved in the control of neural cell proliferation and dierentiation, we have recently identi®ed npdc-1, a gene speci®cally expressed in the nervous system when neural cells stop to divide and enter their terminal dierentiation (Galiana et al, 1995; Dupont et al., 1998) . The encoded protein does not belong to any known family, though the presence of a HLH-like domain has been suggested by four dierent secondary structure predictive methods (Chou and Fasman, 1978; Biou et al., 1988; Unger et al., 1989; Lemesle-Varloot et al., 1993) . It has been shown that the transfection of transformed cells with expression vectors for NPDC-1, results in the suppression of the transformed characteristics of the cells (Galiana et al, 1995; Dupont et al., 1998) . We have also observed that the addition of anti-sense oligonucleotides is able to reverse the biological eects of NPDC-1 expression, indicating that these eects are well-due to NPDC-1 expression (Galiana et al, 1995) . Regarding its biological properties, NPDC-1 displays some similarity with necdin that has been shown to down-regulate the proliferation of neuronal precursor cells (Taniura et al., 1998) .
Therefore, we wondered whether NPDC-1 could interact with cell cycle regulatory proteins. Using a fusion protein between glutathion-S-transferase (GST) and NPDC-1, we observed that NPDC-1 is able to interact in vitro with several proteins involved in the progression of the cell cycle: E2F-1, DP-1, D-cyclins and Cdk2. A two-hybrid approach in mammalian cells, using fusion proteins such as NPDC-1 associated to Gal4 DNA-binding domain and E2F-1 linked to VP16 activating domain, showed that NPDC-1 and E2F-1 can interact together also in vivo. Electrophoretic mobility shift experiments indicated that NPDC-1 reduces the DNA-binding ability of E2F-1. Finally, cotransfection experiments showed that NPDC-1 aects the transcription of a reporter gene associated to a promoter carrying E2F-binding sites.
Results

NPDC-1 interacts in vitro with several cell cycle proteins
The capacity of NPDC-1 to down-regulate cell proliferation (Galiana et al., 1995) prompted us to examine whether it could interact with proteins involved in the progression or the regulation of cell cycle. To investigate the proteins interacting with NPDC-1, we immobilized a GST-NPDC-1 fusion protein onto glutathione-agarose beads (Dupont et al., 1998) . Whole lysates from diverse cell lines metabolically labeled with [ 35 S]methionine were incubated with either GST-NPDC-1 or GST, immobilized on the beads. After extensive washing, the bound proteins were resolved by SDS ± PAGE electrophoresis. The migration pattern showed that several proteins were bound exclusively to GST-NPDC-1, as illustrated in Figure 1a .
Since we suspected that some of these proteins could correspond to cell cycle regulators, we examined whether these proteins could react with antibodies directed against cell cycle regulators that have the same apparent molecular weights as the main proteins revealed in Figure 1a . Some immunoblot experiments are illustrated in Figure 1b , showing that NPDC-1 was able to interact at least with cyclin D1, cdk2 and cyclin A, either directly or indirectly. As illustrated in the lower panel of Figure 1b , we did not observe an interaction between NPDC-1 and cdk4, nor we did between NPDC-1 and either cdk6, p21, or p27 (data not shown). Two other proteins bound to GST-NPDC-1 displayed molecular weights (64 and 56 kDa) similar to those of E2F-1 and DP-1. However, the available antibodies against E2F-1 did not allow the endogenous E2F-1 to be detected by immunoblotting unless strongly concentrated by immunoprecipitation, as reported (Yamasaki et al., 1996) . This prompted us to synthetize these proteins in vitro, in the presence of [ 35 S]methionine, and to examine their binding to GST-NPDC-1. The results in Figure 1d indicated that NPDC-1 was able to interact with in vitro-synthetized E2F-1 and DP-1. Similar experiments showed that NPDC-1 interacted also with in vitro-synthetized cyclins D1, D2, D3 and Cdk2, whereas it did not with cyclin A (Figure 1d) , suggesting that the abovementioned interaction between NPDC-1 and cyclin A was indirect. In Figure 2b , it can be observed that NPDC-1 was also able to interact with GST-NPDC-1 and thus probably to homodimerize.
In addition, converse experiments in which agarose beads coated with GST-E2F-1 or GST-DP-1 were incubated with in vitro-translated NPDC-1 con®rmed that NPDC-1 had the capacity to interact with E2F-1 and DP-1 (Figure 2b ).
Regions of NPDC-1 involved in the interaction with E2F-1 Since E2F/DP complexes have been shown to be involved in the molecular connections between the control of cell cycle and of dierentiation (reviewed by Helin, 1998) , we decided to focus our eorts towards the study of the interaction of NPDC-1 with E2F-1/ DP-1. In order to determine the NPDC-1 domain interacting with E2F-1 and DP-1, various regions of NPDC-1 were deleted, and the truncated forms of the protein were synthetized and labeled in vitro. They were then incubated with GST-E2F-1 or GST-DP-1 immobilized on glutathione-agarose beads and the bound proteins were subjected to SDS ± PAGE electrophoresis. The results in Figure 2 indicated that deletions of the HLH-like domain (DHLH, from aminoacid 100 to 143), or of the MAP-kinases consensus sites (DMAP, from aminoacid 232 to 298), did not aect the in vitro interaction of NPDC-1 with either E2F-1 or DP-1. Regarding the membranebinding hydrophobic region (DMB, from aminoacid 193 to 229), the fact that a weak signal was reproducibly observed with GST alone impedes to conclude that DMBNPDC-1 interacts with the fusion proteins GST-NPDC-1, GST-E2F1 or GST-DP-1, even if the signals were higher than that observed with GST. In contrast, the results in Figure 2 suggested that a long C-terminal deletion (DCterm, from aminoacid aa 149 to 332) reduced this interaction. In comparison, the deletion of the region from aminoacid 11 to 99 (DNterm) completely abolished the interaction. This region contained a long hydrophobic stretch of aminoacids (residues 18 ± 34). Interestingly, the results in Figure 2 indicated also that the same region was required for the homodimerization of NPDC-1.
NPDC-1 and DP-1 bind to overlapping regions of E2F-1 Reciprocally, to identify the E2F-1 domains involved in the binding of NPDC-1, we used a set of GST-E2F-1 deleted forms (Helin et al., 1992) . As illustrated in Figure 3a , we observed that E2FD5, deleted from aminoacid 284 up to the C-terminus was still able to bind NPDC-1. Interestingly, this deleted form retained the domain of interaction with DP-1 (aminoacids 150 ± 284; Helin et al., 1992) . In contrast, E2FD6 deleted from residue 150 up to the C-terminus, was severely Each experiment was repeated four times impaired in binding NPDC-1. The E2FD2 form, with a large N-terminal deletion up to aminoacid 223, but retaining a short segment of the region interacting with DP-1, displayed a reduced capacity to interact with NPDC-1, whereas the shorter forms E2FD3 and E2FD4 (deleted from N-terminus up to residue 314 or 386, respectively) failed to interact with NPDC-1. These observations suggested that NPDC-1 and DP-1 may bind either to the same region or to overlapping regions of E2F-1. To test this hypothesis, we examined the interaction of E2F-1 with DP-1, in the presence of various concentrations of NPDC-1. The results in Figure 3d , indicated that NPDC-1 can completely displace DP-1 from its complex with E2F-1.
NPDC-1 interacts in vivo with E2F-1
The question arose as to whether the NPDC-1/E2F-1 interaction could also occur in vivo. In a ®rst set of experiments, we used an antibody directed against NPDC-1 to precipitate proteins extracted from CLT.T.1.1 or NIH3T6 metabolically labeled with [ 35 S]methionine. As shown in Figure 4a , several proteins co-immunoprecipitated with endogenous NPDC-1, which were not detectable in controls performed with non-immune serum or with anti-GST antibodies. One of them displayed the same apparent molecular weight as E2F-1. However, this co-immunoprecipitated protein could not be identi®ed by immunoblotting with an antibody to E2F-1 for the reason mentioned in the ®rst paragraph.
To obtain further evidence for an in vivo interaction between NPDC-1 and E2F-1, we used a two-hybrid approach in U2OS cells. On one side, we constructed vectors encoding fusion proteins carrying the DNAbinding domain of Gal4 (DBD), fused to NPDC-1 or to its deleted forms NPDCDNterm (i.e. NPDCD11-99) or NPDCDMB (i.e. NPDCD193-229). On the other side, we constructed a vector where VP16 was fused to E2F(D292-414), a form deleted of the activating/ squelching region of E2F-1 (Magae et al., 1997) . The vectors were then cotransfected into the cells, together with a construct (pG5E1b-luc) carring ®ve ®xation sites for Gal4, fused to the adenovirus E1b promoter, upstream to the luciferase reporter gene. As shown in Figure 4b , the expression of the luc reporter gene was . For the sake of clarity, the E2F-1 domains are abbreviated as follows: cyclin/cdk: cyclin/cdk binding region, DNA: DNA-binding domain, DD: dimerisation domain, TA: transactivation region, UB: ubiquitination domain, Rb: pRb family proteins-binding region. GST-E2F-1D2 carries the aminoacids 223 ± 437 of E2F-1, GST-E2F-1D3 retains aminoacids 314 ± 437, GST-E2F-1D4 conserves aminoacids 386 ± 437, GST-E2F-1D5 keeps aminoacids 1 ± 284. GST-E2F-1D6 retains aminoacids 1 ± 150. Bound proteins were resolved by 10% SDS ± PAGE and detected by¯uorography. Results from a typical experiment are illustrated in (a) and summarized in (c). In (d), the eect of various concentrations of NPDC-1 on the binding of DP-1 to E2F-1 is illustrated. For this particular experiment, the GST pull-down assays were performed with 0.2 mg GST-E2F-1 puri®ed from bacteria, 1.5 ng in vitrosynthetized DP-1, and either: 50 ml reticulocyte lysate (Rabbit RL), or 50 ml of lysate containing 30, 45, 60 ng in vitro-synthetized NPDC-1 (lanes indicated NPDC-1620, NPDC-1630, NPDC-1640, respectively). On the right side of (d), the lane referred as GST+DP-1 corresponds to a control where DP-1 was incubated with GST, instead of GST-E2F-1. For every incubation, the ®nal volume was adjusted to 50 ml with the reticulocyte lysate. Each experiment was repeated four times enhanced when the two fusion proteins were cotransfected. The activation of expression of the luc reporter gene was very likely due to the interaction between NPDC-1 and E2F-1. Indeed, this activation was suppressed by the deletion of the sequence from aminoacid 11 to 99 (DNterm), which corresponds to a region involved in the in vitro interaction of NPDC-1 with E2F-1, as mentioned above (see Figure 2) . A second region (aminoacids 193 ± 229, absent in DMB), including a hydrophobic domain, was also necessary for NPDC-1/E2F-1 in vivo interaction (Figure 4b) . Thus, both of these regions appeared to be required when NPDC-1/E2F-1 interaction occurred in vivo.
NPDC-1 inhibits the DNA-binding activity of E2F-1/DP-1
The eect of NPDC-1 on the binding of E2F-1/DP-1 to DNA was tested by using an electrophoresis mobility shift assay (EMSA). The binding of in vitrosynthetized HA-tagged E2F-1 to the E2F-probe was strongly enhanced by the addition of DP-1, as shown in Figure 5a (lanes 2, 4) . The addition of a 50-fold excess of the unlabeled probe suppressed the signal, whereas the addition of a mutated oligonucleotide (AT instead of CG in position 13 ± 14) did not aect the binding of E2F-1/DP-1 to the labeled probe (Figure 5a , lanes 4 ± 6), showing that the binding was speci®c of the E2F-site. The speci®city of the binding of E2F-1/ DP-1 was also veri®ed by the addition of anti-HA antibodies, which resulted in a supershift of the probe (Figure 5a, lane 7) .
The eect of NPDC-1 on the capacity of E2F-1/DP-1 to bind DNA was assayed by incubating in vitro translated E2F-1, DP-1 and the probe with increasing amounts of in vitro translated NPDC-1. The results in Figure 5b (lanes 4 ± 9) indicated that NPDC-1 inhibits the binding of E2F-1/DP-1 to DNA, in a dosedependent manner. The same eect was observed with GST-NPDC-1, GST-E2F-1 and GST-DP-1 puri®ed from bacteria (Figure 5c ). Furthermore, results in Figure 5f indicated that the eect of NPDC-1 on the binding of E2F-1/DP-1 to DNA was independent on the order of addition of the dierent components. Noticeably, NPDC-1 was able to act on a preformed complex between E2F-1/DP-1 and DNA.
As shown in Figure 5e , the NPDC-1 deleted forms which were unable to bind E2F-1 in vivo, i.e. NPDCDNterm or NPDC-DMB, did not aect the binding of E2F-1/DP-1 to DNA, indicating that the inhibition of the binding of E2F-1/DP-1 to DNA, observed in Figure 5b , was likely due to the interaction between E2F-1/DP-1 and NPDC-1.
To investigate whether ectopic expression of NPDC-1 in U2OS cells could aect the DNA-binding activity of endogenous E2F complexes, we transfected the cells with pCMV-NPDC-1 and we examined the binding of the whole cell-extract proteins to the probe. The results in Figure 5d showed that the expression of NPDC-1 in the transfected cells resulted in a decrease of the binding of endogenous E2F complexes to E2F sites.
Effect of NPDC-1 on the transcriptional activity of E2F-1
We examined the eect of NPDC-1 on the transcriptional activity of endogenous E2F, without transfecting E2F-1 expression vector, since the surexpression of E2F-1 leads to a transcriptional squelching (Magae et al., 1997) . Thus, the U2OS cells were cotransfected with a vector expressing the luciferase reporter gene In vivo interaction between NPDC-1 and E2F-1 revealed by two-hybrid assay in mammalian cells. U2OS cells (10 6 cells per 60 mm dishes) were transfected with 2 mg of luciferase reporter gene construct containing the E1b promoter linked to ®ve Gal4 ®xation sites (pG5E1b-luc) and 2 mg of each indicated expression plasmid. The total amount of DNA was adjusted to 7 mg per 10 6 cells with empty pG5E1b plasmid. Cells were harvested 48 h after transfection and the luciferase activity was determined. Error bars represent the standard error from 12 independent experiments
Interactions of NPDC-1 with E2F-1 I Sansal et al from a promoter carrying four E2F binding sites (pE2-luc) and various amounts of pCMV-NPDC-1 vector. In a ®rst set of experiments, a vector expressing the lacZ gene from the CMV promoter (pCMV-lacZ) was co-introduced, with the aim to normalize the luciferase activity to the b-galactosidase activity. We observed that NPDC-1 reduced by about two times (as estimated after normalization) the level of expression of the luciferase gene from the E2 promoter. However, since the pCMV-lacZ expression itself was also decreased by NPDC-1, we intended to verify whether the normalization could be considered as correct. With this aim, in a second set of experiments, we replaced the pCMC-lacZ by a vector pCMV-GFP, expressing the Green Fluorescent Protein (GFP) and we sorted the cells expressing this protein. The determination of the luc activity on the sorted cells con®rmed that the luciferase gene expression from the E2 promoter decreased two times when pCMV-NPDC-1 was cotransfected (Figure 6a) . Such a decrease was not observed with NPDC-DNterm, suggesting that the eect of NPDC-1 on E2 promoter activity was well due to the interaction of NPDC-1 with E2F (Figure 6a ). Then, in order to work on a more de®ned cell subpopulation, expressing GFP as homogeneously as possible, we selected the cells ranging within a window of uorescence intensity, the narrowness of which was limited by the number of cells necessary to determine the luciferase activity. The results in Figure 6b indicated that in such selected cells the luc expression from the E2 promoter decreased 2.5 times in the presence of NPDC-1.
Discussion
In this study, we have looked for proteins which are able to interact with NPDC-1. We have focused our investigation toward cell cycle regulatory proteins, since previous observations showed that NPDC-1 down-regulates cell proliferation (Galiana et al., 1995) .
The analysis of the proteins bound to a GST-NPDC-1 fusion protein revealed that NPDC-1 is able to interact with E2F-1, DP-1, cyclins D1, D2, D3, and The binding to the probe of puri®ed GST-E2F-1 (25 ng) and GST-DP-1 (25 ng) was assayed in the absence (/) or in the presence of puri®ed GST-NPDC-1 (25 or 50 ng). (d) Whole-cell extract (5 mg total protein) of U2OS cells transfected with either empty pCMV (/) or pCMV-NPDC-1 (NPDC-1) were assayed for the binding to the probe. Oligonucleotide competition experiments were done as described in (a) (comp wt or comp mt). (e) The binding of in vitro-synthetized E2F-1-HA and DP-1 to the probe was examined in the absence or presence of in vitro-synthetized NPDC-1 or its indicated deleted forms (in sixfold molar excess as compared to E2F-1-HA). (f) In vitrosynthetized E2F-1-HA, DP-1 and NPDC-1 (relative molar amounts: 1, 1, 5, respectively) and the probe were pre-incubated together simultaneously or sequentially (as illustrated in the right side of the panel) before the addition of the probe. Every experiment was repeated four times cdk2. Since NPDC-1 can interact with these proteins synthetized in vitro, it is very likely that these interactions are direct, though we cannot formally exclude that the reticulocyte lysate used for the in vitro translation could contain an intermediate partner. In contrast, the interaction of NPDC-1 with cyclin A was detected only when cell protein extracts were used as a source of cyclin A, not with in vitro-synthetized cyclin A. This suggests that the interaction of NPDC-1 with cyclin A is indirect, probably through the interactions of NPDC-1 with E2F-1 and/or cdk2. Though we clearly observed direct interactions with cyclins D1, D2 and D3, we were unable to detect any interaction between NPDC-1 and cdk4 or cdk6. Additional experiments are being undertaken to determine whether a competition for D-cyclins could occur between NPDC-1 and cdk4 or cdk6.
We have analysed more particularly the interaction of NPDC-1 with E2F-1. The binding of E2F-1 to various deleted forms of NPDC-1 and reciprocally, the binding of NPDC-1 to deleted forms of E2F-1 have been examined. The results have shown that a region of NPDC-1 included between aminoacid 11 and 99 is necessary for the in vitro binding of NPDC-1 to E2F-1. Reciprocally, the E2F-1 region involved in these interactions lays between aminoacids 150 and 284. This region includes the DP-1-binding domain of E2F-1 (Helin et al., 1992) . Thus its appears that NPDC-1 and DP-1 bind to the same region or to overlapping regions of E2F-1. Moreover, NPDC-1 is able to displace DP-1 from its complex with E2F-1. This suggests that NPDC-1 might compete with DP-1 to bind E2F-1.
In order to determine whether NPDC-1 and E2F-1 can also interact in vivo, we have used a two-hybrid approach. A vector expressing the DNA-binding domain of Gal4 (Gal4DBD) fused to NPDC-1 and a vector expressing the VP16 activating domain fused to E2F1 (deleted from its own activating/squelching domain; Magae et al., 1997) have been co-introduced into the U2OS cells, together with a vector carrying the luciferase reporter gene controlled by a promoter including ®ve recognition sites for Gal4. These cotransfections have resulted in an increase in the luciferase gene expression, indicating that NPDC-1 and E2F-1 are able to interact together in vivo. The activation was only between two-and threefold, as compared to the controls. This low amplitude, probably re¯ects the fact that the interaction of NPDC-1 with E2F-1 is weaker than that observed with classical HLH proteins. Nevertheless, the existence of this interaction is con®rmed by the fact that two deleted forms of NPDC-1 (DNtermNPDC-1 and DMBNPDC-1) do not lead to any stimulation of the luciferase gene expression. Moreover, this observation shows that the NPDC-1 region from aminoacid 11 to 99, which is involved in the NPDC-1/E2F-1 in vitro interaction, is also necessary for the in vivo interaction. In addition, another NPDC-1 region (aminoacids 193 ± 229) is needed for the in vivo interaction even if its deletion (DMB) did not lead to clear-cut results in the GST pull-down assay. These observations are consistent with the results showing that both regions are necessary to the NPDC-1-mediated decrease of the E2F-1 DNA-binding activity.
The capacity of NPDC-1 to interact with E2F-1 and DP-1 and to reduce the ability of E2F-1/DP-1 to bind DNA has suggested that NPDC-1 could aect the transcriptional activity of E2F-1. This point has been examined by following the eect of NPDC-1 on the expression of pE2-luc. In a ®rst time, the data have been normalized to the expression of the lacZ gene from the CMV promoter. However, since we observed a decrease in the expression of the CMV-lacZ itself, we doubted on the accuracy of the normalization. Hence we cotransfected a pCMV-GFP vector along with pCMV-NPDC-1 and pE2-luc. The cells expressing GFP have been sorted, and the luciferase activity has been determined on the sorted cells. Then, to ensure the validity of the results, we have selected a cell subpopulation expressing GFP as homogeneously as possible. Even though the decrease in the expression of pE2-luc has remained limited to 2.5 times, the results clearly indicate that NPDC-1 is able to reduce the transcriptional activity of E2F.
Taken together, the results show that NPDC-1 is able to interact with E2F-1 and DP-1, to reduce its DNA-binding capacity and to inhibit its transcriptional activity. These observations may be related to the negative eect of NPDC-1 on cell proliferation previously described (Galiana et al., 1995) . Thus, the present study suggests that the interaction of NPDC-1 with E2F-1 migth inhibit cell cycle progression by aecting the functions of E2F-1. Since it has also been Figure 6 Eect of NPDC-1 on the E2F transcriptional activity. U2OS cells (4610 6 cells per 100 mm dish) were transfected with 6 mg of pE2-luc, 2 mg of pCMV-GFP, and 13 mg of pCMV-NPDC-1-HA or of pCMV-NPDCDNterm or of empty pCMV. Two days later, 5610 6 cells were sorted by using a BectonDickinson Facs Vantage SE, with a 365 nm excitation wavelength and a 510 nm emission wavelength. For the experiments illustrated in (a), 5610 5 GFP-expressing sorted cells were pooled, lysed, and the luciferase activity was determined; the value obtained for the control (corresponding to the transfection with pE2-luc pCMV-GFP and empty pCMV) was normalized to 100%. All the procedure was repeated three times. For the experiments illustrated in (b), the cells were transfected and sorted similarly, except that the window of¯uorescence intensity of the selected cells was more narrow: this intensity ranged from 4610 2 to 10 3 units (for a whole scale reaching 10 4 arbitrary units). For this selection, which needed ®vefold more cells to be sorted, we did not repeat the assays with pCMV-NPDCDNterm. Nevertheless the whole procedure was repeated twice observed in this work that NPDC-1 is able to interact with D-cyclins, an additional possibility could be that its interaction with D-cyclins might aect a function of the complexes between D-cyclins and cdk4/6, for instance by inhibiting their pRB-phosphorylating activity. However, this hypothesis remains to be investigated.
Materials and methods
Plasmids
The pGST-NPDC-1 plasmid has been previously described (Dupont et al., 1998) . To introduce the Hemagglutinin (HA) tag at the 3'-end of NPDC-1 coding sequence, a polymerase chain reaction (PCR) was performed between oligonucleotide TGAATTCGAAGCATGGCGACGCCCGTC (EcoRI followed by NPDC-1 5'-end) as the sense primer and oligonucleotide TTCCTAGGAATTCTCAGGCATAATCT-GGCACATCATAAGGGTACTGCAGC GGCGGCAAGG-AATGGGGACC (complementary to NPDC-1 3'-end followed by HA sequence and EcoRI site) as the anti-sense primer. The PCR-fragment was then cloned at the EcoRI site of pKS2 plasmid. To allow NPDC-1-HA to be expressed either from the T7 promoter or from the cytomegalovirus immediate ± early promoter (CMV), the NPDC-1-HA DNA was inserted between KpnI and BamHI sites of pCDNA3 (Invitrogen). Constructs expressing NPDC-1 deleted forms were generated from pCMV-NPDC-1 by excising various regions: for NPDCDHLH, the sequence coding for amino acids 99 ± 143 (ClaI ± HincII fragment); for NPDCDMAP, the sequence encoding amino acids 232 ± 298 (Bsp120 ± StuI fragment); for DSmaI, the sequence coding for amino acids 149 ± 332 (SmaI ± EcoRI fragment); for NPDCDNterm, the sequence encoding amino acids 11 ± 99 (SacII ± ClaI fragment). To construct pCMV-NPDCDMB deleted from the sequence coding for amino acids 193 ± 229, two NPDC-1 fragments were ampli®ed by PCR. The ®rst one (nucleotides 152 ± 588) was ampli®ed between the oligonucleotide TGCACTGAAGAGGCGGGCAA, as the sense primer and the oligonucleotide TGCATGCATGAGCACAAGGGT-GAGGCCATT, as the anti-sense primer. This fragment was then digested with ClaI and NsiI. The second fragment (nucleotides 695 ± 969) was ampli®ed between the oligonucleotide TGCATGCATACAGCTAAGGGGCCCACTTCA as the sense primer and the oligonucleotide GTGCTGA-CAGCGTGGAATGG as the antisense primer. This fragment was then digested with NsiI and StuI. The two fragments were ligated together and inserted between ClaI and StuI sites of pCMV-NPDC-1.
The pGST-E2F-1, pGST-E2F-1D2 (aa 223 ± 437), pGST-E2F-1D3 (aa 314 ± 437), pGST-E2F-1D4 (aa 386 ± 437), pGST-E2F-1D5 (aa 1 ± 284) and pE2-luc plasmids were kindly provided by K Helin (Helin et al., 1992) . pGST-E2F-1D6 was generated from pGST-E2F-1 by excising a SalI ± EcoRI fragment (corresponding to the sequence encoding amino acids 150 ± 437).
The pM vector (expressing the Gal-4 DNA-binding domain from SV40 early promoter) pVP16 (expressing the acidic domain of the Herpes Simplex Virus-1 VP16 transactivator), pCMV-lacZ and pCMV-GFP vectors were from Clontech. The pG5E1b-luc vector expressing the luciferase gene from the adenovirus E1b promoter fused to ®ve Gal4-recognition sites was provided us by S Leibovitch. To obtain pM-NPDC-1, the NPDC-1 cDNA was subcloned into the EcoRI site of pM. The pVP16-DE2F-1 construct was generated by subcloning the BamHI ± EcoRI fragment of DE2F-1 (E2F-1 deleted from the ClaI ± XhoI fragment encoding aminoacids 292 ± 414) between the BamHI and EcoRI sites of pVP16.
Each construct was veri®ed by partial sequencing, using a dye terminator cycle sequencing ready reaction kit with amplitaq DNA polymerase TS (Perkin Elmer). Reaction products were analysed using an ABI PRISM -310 Genetic Analyzer (Perkin Elmer).
Expression and purification of GST fusion proteins
GST-E2F-1 and GST-DP1 fusion proteins were expressed and puri®ed from E. coli as described (Helin et al., 1993a; Xu et al., 1994) . GST-NPDC-1 was expressed and puri®ed as previously reported (Dupont et al., 1998) .
Cell cultures, and metabolic labelling
The cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum at 378C in a humidi®ed 5% CO 2 atmosphere. For radioisotopic labeling, cells were incubated for 3 h at 378C in 2 ml of methioninefree media supplemented with 100 mCi of [ 
Cell lysis
Protein extracts were prepared essentially as described (Harlow and Lane, 1988) , with minor modi®cations. Brie¯y, the cells were lysed by incubation in RIPA buer (1 ml per 5.10 6 cells): 50 mM Tris (pH 8.0) containing 150 mM NaCl, 1% Nonidet-P40 (NP-40), 0.5% Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), supplemented with 2 mM PMSF, 20 mM leupeptin, 20 mM pepstatin, 1 mg/ml aprotinin, for 30 min at 48C. The extracts were centrifuged at 12 000 g for 10 min. The supernatants were used immediately for immunoprecipitation, or GST pull-down assays, or Western blot analysis. For gel-retardation assays, the cells were lysed in 1 ml 20 mM HEPES (pH 7.5) containing 200 mM NaCl, 2.5 mM DTT, 0.5% NP40, supplemented with 5 mM NaF, 0.5 mM orthovanadate and the above-mentioned protease inhibitors. Protein concentration was determined according to Bradford's method.
Immunological reagents
The polyclonal antibody to NPDC-1 was generated by immunizing rabbit with emulsi®ed GST-NPDC-1. Anti-HA antibody (12CA5) was from Boehringer Mannheim. Anti-E2F-1 (KH95X), anti-DP1 (K-20X), anti-cdk2 (M2) and anti-cyclin D1 (HD11) were from SantaCruz Biotechnology. Anti-RB (XZ55) was from Pharmingen and peroxydaseconjugated antibodies against mouse or rabbit immunoglobulins from Sigma.
In vitro transcription-coupled translation
The proteins were synthetized in rabbit reticulocyte lysate using the TNT lysate system (Promega), according to the manufacturer's instructions. Proteins were synthetized in the presence of [ In vitro-binding experiments GST pull-down experiments were performed as previously described (Dupont et al., 1998) . Unless otherwise stated, in vitro translation products (5 ml containing 10 ± 20 ng of the synthetized protein) or protein extracts (40 mg) were incubated with glutathione-agarose beads loaded with 10 mg of GST or GST-NPDC-1. The incubation was carried out in 50 mM Tris (pH 7.5) containing 120 mM NaCl, 0.5% NP-40, 1 mM dithiothreitol (DTT), supplemented with the abovementioned protease inhibitors, for 2 h at 48C. The beads were washed with 500 mM NaCl in the same buer solution.
Bound proteins were resolved by 10% SDS-polyacrylamide gel electrophoresis (SDS ± PAGE). The 35 S-labeled proteins were detected by¯uorography. The non-labeled proteins were analysed by immunoblot using the appropriate antibodies and revealed by chemiluminescence according to the instructions of the manufacturer (Amersham ECL system).
Immunoprecipitation
35
S-labeled cell extracts (200 ml), previously cleared with preimmune-serum (NIS), were incubated for 1 h at 48C with 400 ml of NETgel-buer (50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% NP40, 0.25% gelatin, 0.02% sodium azide) and 5 ml of the indicated antibodies. Subsequently, 20 ml of 50% (w/v) slurry protein-A sepharose was added. The samples were rocked for 30 min at 48C, then washed ®ve times in RIPA buer. The immunoprecipitated proteins were separated by 10% SDS ± PAGE and visualized by¯uorography.
Transfections
The cells were transfected by the calcium-phosphate procedure, as described (Chen and Okayama, 1987) . For two-hybrid experiments or for transient expression assays, U2OS cells were transiently transfected with 2 mg of luciferase reporter gene downstream to the E1b promoter linked either to ®ve Gal4 ®xation sites (pG5E1b-luc) or to four E2F-1 binding sites (pE2-luc) and 2 mg of each indicated expression or empty vectors. The total amount of DNA was adjusted to 7 mg, with empty vector. For gel-retardation assays, U2OS cells were transiently transfected with 7 mg of either pCMV or pCMV-NPDC-1. Luciferase activity was determined using the Promega system according to the instructions of the manufacturer.
Electrophoretic mobility shift assays
In vitro synthetized proteins (unless otherwise stated, 1 ± 2 ml containing 1 ± 10 ng of the synthetized protein) or GST fusion proteins (typically 10 ± 12 ng) were incubated for 20 min at 378C in 20 mM HEPES (pH 7.5), 40 mM KCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.25% NP40, 5% glycerol and 2 mg of denatured salmon sperm DNA. After addition of 0.2 ng of 32 P-labeled E2F probe, they were incubated for 15 min at room temperature. When cell protein extracts were used, the binding buer contained 20 mM HEPES (pH 7.5), 50 mM KCl, 10 mM MgCl 2 , 0.5 mM DTT, 1% NP40 and 5% glycerol to which 0.5 ng of 32 P-labeled E2F probe and 2 mg of denatured salmon sperm DNA were added. In order to verify the identity of the bound protein, 5 ml of anti-Ha antibodies were added to the binding reaction mixture for a further incubation of 15 min at room temperature. The speci®city of the binding was veri®ed by adding to the binding reaction mixture, a 50-fold excess of the wild-type ATTTA-AGTTTCGCGCCCTTTCTCAA or of the`mutated' ATT-TAAGTTTCGATCCCTTTCTCAA oligonucleotide. The reaction products were then separated by electrophoresis through a 4% polyacrylamide gel.
